A prostanoid receptor EP4 agonist enhances ectopic bone formation induced by recombinant human bone morphogenetic protein-2
- PMID: 15144895
- DOI: 10.1016/j.bbrc.2004.04.080
A prostanoid receptor EP4 agonist enhances ectopic bone formation induced by recombinant human bone morphogenetic protein-2
Abstract
The anabolic effects of prostaglandin E(2) on bone are effected through the activation of EP4, a G protein-coupled receptor. In the present study, we examined the effects of a prostanoid receptor-selective agonist (ONO-4819) in an experimental system of ectopic bone formation using recombinant human bone morphogenetic protein-2 (rhBMP-2). Collagen pellets containing rhBMP-2 were implanted onto the back muscles of mice and then treated with ONO-4819 administered every 8 h by subcutaneous injection. The ossicles elicited ectopically by rhBMP-2 in mice treated with 30 microg/kg ONO-4819 were significantly larger in size and had a higher bone mineral density and bone mineral content when compared to the controls. We also noted that the anabolic effect of ONO-4819 was seen only in the early phase of the rhBMP-2-induced bone-forming process. These experimental results indicate that the EP4 receptor agonist enhances the rhBMP-2-induced bone formation through a selective effect on early stage mesenchymal cells, which in turn may result in increased responsiveness of the host animals to rhBMP-2.
Similar articles
-
Augmentation of bone morphogenetic protein-induced bone mass by local delivery of a prostaglandin E EP4 receptor agonist.Bone. 2005 Oct;37(4):555-62. doi: 10.1016/j.bone.2005.04.042. Bone. 2005. PMID: 16027058
-
Enhancement of recombinant human bone morphogenetic protein-2 (rhBMP-2)-induced new bone formation by concurrent treatment with parathyroid hormone and a phosphodiesterase inhibitor, pentoxifylline.J Bone Miner Metab. 2004;22(4):329-34. doi: 10.1007/s00774-003-0490-y. J Bone Miner Metab. 2004. PMID: 15221490
-
Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading.Bone. 2005 Mar;36(3):444-53. doi: 10.1016/j.bone.2004.12.013. Bone. 2005. PMID: 15777678
-
Prostaglandin E(2) receptors as potential bone anabolic targets - selective EP4 receptor agonists.Curr Mol Pharmacol. 2012 Jun;5(2):174-81. doi: 10.2174/1874467211205020174. Curr Mol Pharmacol. 2012. PMID: 21787288 Review.
-
Prostaglandin EP2 and EP4 receptor agonists in bone formation and bone healing: In vivo and in vitro evidence.Expert Opin Investig Drugs. 2009 Jun;18(6):746-66. doi: 10.1517/13543780902893051. Expert Opin Investig Drugs. 2009. PMID: 19426119 Review.
Cited by
-
RNA interference for noggin enhances the biological activity of bone morphogenetic proteins in vivo and in vitro.J Bone Miner Metab. 2009;27(4):402-11. doi: 10.1007/s00774-009-0054-x. Epub 2009 Feb 28. J Bone Miner Metab. 2009. PMID: 19252814
-
Successful spinal fusion by E. coli-derived BMP-2-adsorbed porous beta-TCP granules: a pilot study.Clin Orthop Relat Res. 2009 Dec;467(12):3206-12. doi: 10.1007/s11999-009-0960-1. Epub 2009 Jul 7. Clin Orthop Relat Res. 2009. PMID: 19582526 Free PMC article.
-
A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart.Heart Fail Rev. 2015 Jul;20(4):401-13. doi: 10.1007/s10741-015-9477-8. Heart Fail Rev. 2015. PMID: 25708182 Free PMC article. Review.
-
Cyclic AMP enhances Smad-mediated BMP signaling through PKA-CREB pathway.J Bone Miner Metab. 2008;26(5):478-84. doi: 10.1007/s00774-008-0850-8. Epub 2008 Aug 30. J Bone Miner Metab. 2008. PMID: 18758906
-
Bioactive and bioresorbable cellular cubic-composite scaffolds for use in bone reconstruction.J R Soc Interface. 2006 Dec 22;3(11):805-21. doi: 10.1098/rsif.2006.0144. J R Soc Interface. 2006. PMID: 17015297 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources